S3V Vascular Technologies Ltd - Unlisted Shares
Fundamentals
- Current Price
- ₹445
- Market Cap
- ₹853.45 Cr
- ISIN
- INE0HGT01012
- Face Value
- ₹10
- EPS
- -1.66
- P/B Ratio
- 6.06
- Book Value
- ₹73.39
- Debt / Equity Ratio
- 0.18
Key Financials
Profit & Loss
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue from Operations | 14.93 | 18.9 | 20.91 | 16.13 |
| Growth % | -21.01% | -9.61% | 29.63% | 16.29% |
| Operating Expenses | 12.58 | 15.29 | 15.32 | 12.4 |
| Growth % | -17.72% | -0.20% | 23.15% | 16.26% |
| Operating Profit | 2.35 | 3.61 | 5.59 | 3.69 |
| Op. Profit Margin % | 15.74% | 19.10% | 26.73% | 22.88% |
| Other Income | 0.23 | 0.08 | 0.1 | 0 |
| Finance Costs | 3.56 | 1.31 | 1.41 | 1.62 |
| Depreciation | 2.07 | 1.73 | 1.48 | 1.41 |
| Exceptional items | 0 | 0 | 0 | 1.09 |
| Profit Before Tax | -3.1 | 0.6 | 2.8 | 2.2 |
| Tax | 0.14 | 0.09 | 0.12 | 0.44 |
| Tax % | -4.59% | 13.85% | 4.27% | 20.37% |
| Profit After Tax | -3.2 | 0.6 | 2.7 | 1.7 |
| Growth % | -669.64% | -79.18% | 56.40% | -176.44% |
| PAT % | -21.37% | 2.96% | 12.86% | 10.66% |
Company Financials
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Equity Capital | 19.2 | 13.2 | 13.0 | 12.9 |
| Reserves | 121.6 | 25.8 | 21.9 | 16.9 |
| Total Equity | 140.8 | 39.1 | 34.9 | 29.7 |
| Financial Laibilities | 11.2 | 21.1 | 8.9 | 11.21 |
| Provisions | 0.4 | 0.3 | 0.0 | 0.0 |
| Other Non-Current Liabilities | 3.4 | 5.3 | 4.6 | 4.3 |
| Total NC Liabilities | 15.0 | 26.8 | 13.6 | 15.5 |
| Short term Borrowings | 14.1 | 8.6 | 11.0 | 7.3 |
| Other Current Liabilities | 7.8 | 5.2 | 4.2 | 10.2 |
| Total Current Liabilities | 21.9 | 13.8 | 15.2 | 17.5 |
| Equity + Liabilities | 177.6 | 79.6 | 63.6 | 62.7 |
| Fixed Assets (incl. WIP) | 25.8 | 20.3 | 18.7 | 18 |
| Other Non Current Assets | 17.9 | 15.2 | 4.1 | 7.7 |
| Total NC Assets | 43.6 | 35.5 | 22.8 | 26.1 |
| Trade Receivables | 37.1 | 34 | 31.6 | 25.1 |
| Cash & Cash Equivalents | 77 | 1.6 | 0.8 | 3.3 |
| Other Current Assets | 19.9 | 8.6 | 8.4 | 8.3 |
| Total Current Assets | 134.0 | 44.2 | 40.8 | 36.7 |
| Total Assets | 177.6 | 79.6 | 63.6 | 62.7 |
Shareholding Pattern
- N G Badari Narayan
- 16.76%%
- Kalindhi Narayan
- 8.43%%
- Vijaya Gopal Nagaragadde
- 6.12%%
- Vishnu Shreyas
- 5.05%%
- Srivatsa Sarang
- 4.69%%
- L&T Welfare Company Limited (CCPS)
- 7.41%%
- Mahima Stocks Private Limited (CCPS)
- 5.63%%
- Others
- 45.91%%
Strengths & Weaknesses
Strengths
- Strong Investor Confidence: The company is backed by prominent investors, including Mr. A.M. Naik (former Chairman of L&T) and Mr. Madhusudan Kela and raised around 300 Cr from such investors in their ‘Series B’ round.
- Government Backed: S3V is in process to build India's First Neuro-Intervention Integrated Manufacturing Plant for Stroke Treatment and is backed by the Technology Development Board (TDB), Department of Science and Technology (DST).
- Industry Growth: Industry experts project the Indian medical devices market to reach $50 billion by 2025, growing at an impressive annual rate of 15 to 20 percent, outpacing the global industry.(Source:Economic Times)
- Business Growth: The company aims to integrate these devices into government reimbursement programs such as Ayushman Bharat, thereby unlocking a domestic market estimated at 2 Billion USD
Weaknesses
- Regulatory & Clinical Approval Risks: The company is currently initiating CE certification and seeking USFDA approval for its next-generation products, including neuro-intervention devices. Delays or failures in achieving these certifications could severely hinder market access.
- High Capital Requirements: The company relies on venture capital, angel networks, and government support (TDB) for funding. Sustaining research, development, and trials without immediate, large-scale revenue could pose financial risk.
About S3V Vascular Technologies Ltd
S3V Vascular Technologies is a medical device company based in India and incubated at “Indian School of Business (ISB)”. It focuses on developing and manufacturing advanced medical devices to treat cardiovascular diseases (conditions affecting the heart and blood vessels). S3V Vascular Technologies is set to become the first Indian company to indigenously design and manufacture the complete suite of neuro-intervention devices, including microcatheters, aspiration catheters, guidewires, and stent retriever systems in an upstream integrated facility. The company also intends to file patents for critical innovations such as the clot retriever head design, braid-over-coil aspiration catheter structures, and several advanced process technologies
Board of Directors
- Vijaya Gopal Nagaradagadde - Managing Director
- Badari Narayan Nagarada Gadde - Whole Time Director
- Nagarada Gadde Vishnu Shreyas - Whole Time Director
- Veeresham Ciddi - Independent Director
- Prithi Sureka Mummidi - Independent Director
- Govindan Ramaswamy - Independent Director
- Mr. Narayan Kalindhi - Non-Independent Director
- Mr. Narendra Kumar Srisrimal - Non-Independent Director
- Mr. Venkateswara Gowtama Mannava - Non-Independent Director
- Mr. Dip Kishore - Non-Independent Director
Senior Management
- Badari Narayan Nagarada Gadde - Chief Executive Officer
- Nagarada Gadde Vishnu Shreyas - Chied Financial Officer
- Mr. Anuj Mehta - Company Secretary
